SINDAS / 胸部放疗 III期：EGFR 突变寡转移中局部放疗的随机证据
类型: III期临床试验 / 放疗 发表日期: 2024-10-07 入库日期: 2026-05-21 来源: PubMed / JNCI / Journal of Clinical Oncology 标签: EGFR L858R, 放疗, 寡转移, 胸部放疗, SINDAS, TKI, 局部治疗
Citations
Wang XS, et al. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC. Journal of the National Cancer Institute. 2023. PMID: 35094066. DOI: 10.1093/jnci/djac015
Sun X, et al. Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic NSCLC Treated With EGFR-TKIs: A Multicenter, Randomized, Controlled, Phase III Trial. Journal of Clinical Oncology. 2025. PMID: 39374473. DOI: 10.1200/JCO.23.02075
Why it matters for mom
Mom is not at initial diagnosis anymore, so these trials should not be applied mechanically. They matter because they show that, in selected EGFR-mutated patients with limited metastatic burden or oligo-organ disease, local radiation added to systemic EGFR-TKI therapy can be more than symptom care.
For mom, the question is whether any lesion is behaving like an oligoprogressive or locally threatening site while the rest of disease is controlled enough to justify local treatment.
Practical takeaways
- Local therapy is most persuasive when disease is limited, anatomy is safely targetable, and systemic therapy still controls most other disease.
- The family should ask doctors to classify progression pattern: oligoprogression, oligo-residual disease, diffuse systemic progression, or symptomatic bone threat.
- Radiation decisions should include biopsy timing, because radiating the best biopsy target first can reduce later diagnostic yield.
- These trials strengthen the reason to consult radiation oncology early, not only after severe pain.
Questions for doctors
- Does her sternum/parasternal lesion represent oligoprogression, symptomatic/structural bone disease, or broad systemic progression?
- Should biopsy happen before radiation to evaluate resistance or transformation?
- If radiation is done, should osimertinib or chemotherapy be held, continued, or timed around treatment?